타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | enfortumab vedotin-ejfv (Padcev, ASG-22ME, enfortumab-vedotin-ejfv) Astellas / Pfizer (Seagen)·Nectin-4 201 trials | mirvetuximab soravtansine-gynx (Elahere, IMGN853, mirvetuximab-soravtansine-gynx) AbbVie / ImmunoGen·FRα (folate receptor alpha) 32 trials | telisotuzumab vedotin (Emrelis, ABBV-399, Teliso-V, telisotuzumab-vedotin-tllv) AbbVie·c-Met 12 trials·t½ ADC in the range of days; free MMAE shorter | Platinum Based Chemotherapy (Platinum Based Chemotherapy) Merck Sharp & Dohme LLC·Ovarian Cancer 128 trials | |
|---|---|---|---|---|---|
Overview Program | Padcev (enfortumab vedotin-ejfv) | Elahere (mirvetuximab soravtansine-gynx) | Tisotumab Vedotin | Emrelis (telisotuzumab vedotin) | Platinum Based Chemotherapy |
Overview Company | Astellas / Pfizer (Seagen) | AbbVie / ImmunoGen | Genmab / Pfizer | AbbVie | Merck Sharp & Dohme LLC |
Overview Modality | ADC | ADC | ADC | ADC | ADC |
Overview Target | Nectin-4 | FRα (folate receptor alpha) | Solid Malignancies | c-Met | Ovarian Cancer |
Overview Indication | Locally advanced or metastatic urothelial carcinoma | FRα-positive platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Previously treated locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression | Nonsquamous Non-small Cell Lung Cancer; EGFR L858R |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | Nectin-4 is near-uniformly expressed in urothelial carcinoma, giving an unusually clean tumor-selective target in that tissue. | FRα is overexpressed in ovarian cancer but sparse in normal tissue, and the label requires IHC-confirmed expression. | — | Selects high c-Met protein overexpression by IHC, not MET gene mutation. That split is the first row versus MET TKIs. | — |
Positioning Known limitation | Nectin-4 loss, MMAE efflux, and tubulin alterations. | FRα downregulation and multidrug-resistance transporter upregulation. | — | c-Met down-regulation, MMAE efflux, and histologic transformation. | — |
Positioning Development positioning | 1L with pembrolizumab; monotherapy in later lines | 2L–4L platinum-resistant | — | 2L+ | — |
Technology Payload | MMAE (monomethyl auristatin E, tubulin inhibitor) | DM4 (maytansinoid, tubulin inhibitor) | — | MMAE (microtubule inhibitor) | vedotin (ARON-2EV study) |
Technology Linker | Protease-cleavable mc-vc-PAB, DAR ~3.8 | Cleavable sulfo-SPDB disulfide, DAR ~3.5 | — | Cleavable vc linker, vedotin chemistry | — |
Technology DAR | DAR 3.8 | DAR 3.5 | — | — | — |
MoA Mechanism | Binds Nectin-4 on urothelial tumor cells, internalizes, and releases MMAE after cathepsin B cleavage; microtubule disruption arrests mitosis and triggers apoptosis. | Binds FRα, internalizes via receptor-mediated endocytosis, and releases DM4 after disulfide reduction; tubulin disruption causes mitotic arrest, with lipophilic S-methyl-DM4 giving bystander activity. | — | Anti-c-Met antibody binds and internalizes; the protease-cleavable linker releases MMAE, which disrupts microtubules and kills the cell plus neighbors via bystander diffusion. | targeting oxidative stress, hypoxia, persistent DNA damage, immune signaling |
MoA Biomarker | Nectin-4 expression is high in urothelial carcinoma; no companion diagnostic required. | FRα IHC (VENTANA FOLR1 RxDx), PS2+ scoring with ≥75% of tumor cells staining. | — | VENTANA MET (SP44) companion diagnostic. High overexpression is ≥50% of cells with 3+ staining, not MET exon 14 skipping. | biomarker-embedded clinical trials, molecular subtype-stratified patient selection, and rigorous evaluation o |
PK/PD Half-life | — | — | — | ADC in the range of days; free MMAE shorter | — |
PK/PD Animal (cat.) | — | — | — | Human | — |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | Rat | — | — | — |
Toxicology Major finding | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Boxed warning for ocular toxicity — keratopathy, blurred vision, and dry eye. Peripheral neuropathy, nausea, and fatigue are also common. | Pneumonitis: Severe, life-threatening, or fatal pneumonitis may occur | Peripheral neuropathy, fatigue, decreased appetite, and peripheral edema are common. Grade 3–4 lab signals include lymphopenia and transaminase rises. | — |
Toxicology CRS | N/A | N/A | — | N/A | — |
Clinical Safety signal | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Boxed warning for ocular toxicity — keratopathy, blurred vision, and dry eye. Peripheral neuropathy, nausea, and fatigue are also common. | Pneumonitis: Severe, life-threatening, or fatal pneumonitis may occur | Peripheral neuropathy, fatigue, decreased appetite, and peripheral edema are common. Grade 3–4 lab signals include lymphopenia and transaminase rises. | — |
Clinical Selected reported efficacy | 95% | ORR 42% | — | — | — |
Clinical Reported ORR | — | 42% vs 16% (chemotherapy; rounded in NCI report) | — | — | — |
Clinical Reported PFS | 12.5 months vs 6.3 months (platinum chemotherapy) | 5.6 months vs 4.0 months (chemotherapy) | — | — | — |
Clinical Reported OS | 31.5 months vs 16.1 months (platinum chemotherapy) | 16.5 months vs 12.8 months (chemotherapy) | — | — | — |
Clinical Result source | FDA approval report 2023-12-15 — EV-302 (NCT04223856) | NCI approval analysis 2024 — MIRASOL (NCT04209855) | — | — | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | — | No active/completed counts |
Clinical Trial ref | NCT04223856 | NCT04209855 | — | — | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | enfortumab vedotin-ejfv (Padcev, ASG-22ME, enfortumab-vedotin-ejfv) Astellas / Pfizer (Seagen)·Nectin-4 201 trials | mirvetuximab soravtansine-gynx (Elahere, IMGN853, mirvetuximab-soravtansine-gynx) AbbVie / ImmunoGen·FRα (folate receptor alpha) 32 trials | telisotuzumab vedotin (Emrelis, ABBV-399, Teliso-V, telisotuzumab-vedotin-tllv) AbbVie·c-Met 12 trials·t½ ADC in the range of days; free MMAE shorter | Platinum Based Chemotherapy (Platinum Based Chemotherapy) Merck Sharp & Dohme LLC·Ovarian Cancer 128 trials | |
|---|---|---|---|---|---|
Overview Program | Padcev (enfortumab vedotin-ejfv) | Elahere (mirvetuximab soravtansine-gynx) | Tisotumab Vedotin | Emrelis (telisotuzumab vedotin) | Platinum Based Chemotherapy |
Overview Company | Astellas / Pfizer (Seagen) | AbbVie / ImmunoGen | Genmab / Pfizer | AbbVie | Merck Sharp & Dohme LLC |
Overview Modality | ADC | ADC | ADC | ADC | ADC |
Overview Target | Nectin-4 | FRα (folate receptor alpha) | Solid Malignancies | c-Met | Ovarian Cancer |
Overview Indication | Locally advanced or metastatic urothelial carcinoma | FRα-positive platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Previously treated locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression | Nonsquamous Non-small Cell Lung Cancer; EGFR L858R |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | Nectin-4 is near-uniformly expressed in urothelial carcinoma, giving an unusually clean tumor-selective target in that tissue. | FRα is overexpressed in ovarian cancer but sparse in normal tissue, and the label requires IHC-confirmed expression. | — | Selects high c-Met protein overexpression by IHC, not MET gene mutation. That split is the first row versus MET TKIs. | — |
Positioning Known limitation | Nectin-4 loss, MMAE efflux, and tubulin alterations. | FRα downregulation and multidrug-resistance transporter upregulation. | — | c-Met down-regulation, MMAE efflux, and histologic transformation. | — |
Positioning Development positioning | 1L with pembrolizumab; monotherapy in later lines | 2L–4L platinum-resistant | — | 2L+ | — |
Technology Payload | MMAE (monomethyl auristatin E, tubulin inhibitor) | DM4 (maytansinoid, tubulin inhibitor) | — | MMAE (microtubule inhibitor) | vedotin (ARON-2EV study) |
Technology Linker | Protease-cleavable mc-vc-PAB, DAR ~3.8 | Cleavable sulfo-SPDB disulfide, DAR ~3.5 | — | Cleavable vc linker, vedotin chemistry | — |
Technology DAR | DAR 3.8 | DAR 3.5 | — | — | — |
MoA Mechanism | Binds Nectin-4 on urothelial tumor cells, internalizes, and releases MMAE after cathepsin B cleavage; microtubule disruption arrests mitosis and triggers apoptosis. | Binds FRα, internalizes via receptor-mediated endocytosis, and releases DM4 after disulfide reduction; tubulin disruption causes mitotic arrest, with lipophilic S-methyl-DM4 giving bystander activity. | — | Anti-c-Met antibody binds and internalizes; the protease-cleavable linker releases MMAE, which disrupts microtubules and kills the cell plus neighbors via bystander diffusion. | targeting oxidative stress, hypoxia, persistent DNA damage, immune signaling |
MoA Biomarker | Nectin-4 expression is high in urothelial carcinoma; no companion diagnostic required. | FRα IHC (VENTANA FOLR1 RxDx), PS2+ scoring with ≥75% of tumor cells staining. | — | VENTANA MET (SP44) companion diagnostic. High overexpression is ≥50% of cells with 3+ staining, not MET exon 14 skipping. | biomarker-embedded clinical trials, molecular subtype-stratified patient selection, and rigorous evaluation o |
PK/PD Half-life | — | — | — | ADC in the range of days; free MMAE shorter | — |
PK/PD Animal (cat.) | — | — | — | Human | — |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | Rat | — | — | — |
Toxicology Major finding | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Boxed warning for ocular toxicity — keratopathy, blurred vision, and dry eye. Peripheral neuropathy, nausea, and fatigue are also common. | Pneumonitis: Severe, life-threatening, or fatal pneumonitis may occur | Peripheral neuropathy, fatigue, decreased appetite, and peripheral edema are common. Grade 3–4 lab signals include lymphopenia and transaminase rises. | — |
Toxicology CRS | N/A | N/A | — | N/A | — |
Clinical Safety signal | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Boxed warning for ocular toxicity — keratopathy, blurred vision, and dry eye. Peripheral neuropathy, nausea, and fatigue are also common. | Pneumonitis: Severe, life-threatening, or fatal pneumonitis may occur | Peripheral neuropathy, fatigue, decreased appetite, and peripheral edema are common. Grade 3–4 lab signals include lymphopenia and transaminase rises. | — |
Clinical Selected reported efficacy | 95% | ORR 42% | — | — | — |
Clinical Reported ORR | — | 42% vs 16% (chemotherapy; rounded in NCI report) | — | — | — |
Clinical Reported PFS | 12.5 months vs 6.3 months (platinum chemotherapy) | 5.6 months vs 4.0 months (chemotherapy) | — | — | — |
Clinical Reported OS | 31.5 months vs 16.1 months (platinum chemotherapy) | 16.5 months vs 12.8 months (chemotherapy) | — | — | — |
Clinical Result source | FDA approval report 2023-12-15 — EV-302 (NCT04223856) | NCI approval analysis 2024 — MIRASOL (NCT04209855) | — | — | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | — | No active/completed counts |
Clinical Trial ref | NCT04223856 | NCT04209855 | — | — | — |
추천 비교
추천 비교